The estimated CAPEX of $350m was from a *Concept Study* completed some years ago. Any scoping study is not definitive - neither is a PFS. Apart from the disappointing PFS, I cannot note reasons as to how any shareholders have been misled.
- Forums
- ASX - By Stock
- PLV
- fundamentals consideration
fundamentals consideration, page-14
-
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PLV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online